Angelico Mendy1, Erick Forno2, Theophile Niyonsenga3, Ryan Carnahan4, Janvier Gasana5. 1. Department of Occupational and Environmental Health, College of Public Health, University of Iowa, Iowa City, Iowa. 2. Division of Pediatric Pulmonary Medicine, Allergy, and Immunology, Children's Hospital of Pittsburgh of UPMC, University of Pittsburgh, Pittsburgh, Pennsylvania. 3. Faculty of Health, Centre for Research and Action in Public Health, University of Canberra, Canberra, Australia. 4. Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa. 5. Department of Environmental & Occupational Health, Faculty of Public Health, Kuwait University, Jabriya, Kuwait.
Abstract
BACKGROUND: Perceived to be distinct, asthma and chronic obstructive pulmonary disease (COPD) can co-exist and potentially have a worse prognosis than the separate diseases. Yet, little is known about the exact prevalence and the characteristics of the Asthma-COPD overlap (ACO) in the US population. AIMS: To determine ACO prevalence in the United States, identify ACO predictors, examine ACO association with asthma and COPD severity, and describe distinctive spirometry and laboratory features of ACO. METHODS: Data on adult participants to the National Health and Nutrition Examination Surveys conducted from 2007 to 2012 was analyzed. ACO was defined as current asthma and post-bronchodilator forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) <0.7. RESULTS: Overall, 7,570 participants representing 98.58 million Americans were included in our study. From 2007 to 2012, the crude and age-standardized ACO prevalence were, respectively, 0.96% (95% CI: 0.65%-1.26%) and 1.05% (0.74%-1.37%). In asthma, ACO predictors included older age, male gender, and smoking. In COPD, ACO predictors were non-Hispanic Black race/ethnicity and obesity. ACO was associated with increased ER visits for asthma (OR = 3.46, 95% CI: 1.48-8.06]) and oxygen therapy in COPD (OR = 11.17, 95% CI: 5.17-24.12]). In spirometry, FEV1 and peak expiratory flow were lower in ACO than in asthma or COPD alone. CONCLUSION: Age-adjusted prevalence of ACO in the United States was 1.05% in 2007-2012, representing 0.94 (95% CI: 0.62-1.26) million Americans. It is much lower than previously reported. The overlap was associated with higher asthma and COPD severity as well as decreased lung function compared with COPD or asthma alone.
BACKGROUND: Perceived to be distinct, asthma and chronic obstructive pulmonary disease (COPD) can co-exist and potentially have a worse prognosis than the separate diseases. Yet, little is known about the exact prevalence and the characteristics of the Asthma-COPD overlap (ACO) in the US population. AIMS: To determine ACO prevalence in the United States, identify ACO predictors, examine ACO association with asthma and COPD severity, and describe distinctive spirometry and laboratory features of ACO. METHODS: Data on adult participants to the National Health and Nutrition Examination Surveys conducted from 2007 to 2012 was analyzed. ACO was defined as current asthma and post-bronchodilator forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) <0.7. RESULTS: Overall, 7,570 participants representing 98.58 million Americans were included in our study. From 2007 to 2012, the crude and age-standardized ACO prevalence were, respectively, 0.96% (95% CI: 0.65%-1.26%) and 1.05% (0.74%-1.37%). In asthma, ACO predictors included older age, male gender, and smoking. In COPD, ACO predictors were non-Hispanic Black race/ethnicity and obesity. ACO was associated with increased ER visits for asthma (OR = 3.46, 95% CI: 1.48-8.06]) and oxygen therapy in COPD (OR = 11.17, 95% CI: 5.17-24.12]). In spirometry, FEV1 and peak expiratory flow were lower in ACO than in asthma or COPD alone. CONCLUSION: Age-adjusted prevalence of ACO in the United States was 1.05% in 2007-2012, representing 0.94 (95% CI: 0.62-1.26) million Americans. It is much lower than previously reported. The overlap was associated with higher asthma and COPD severity as well as decreased lung function compared with COPD or asthma alone.
Authors: Megan Hardin; Michael Cho; Merry-Lynn McDonald; Terri Beaty; Joe Ramsdell; Surya Bhatt; Edwin J R van Beek; Barry J Make; James D Crapo; Edwin K Silverman; Craig P Hersh Journal: Eur Respir J Date: 2014-05-29 Impact factor: 16.671
Authors: O A Nascimento; A Camelier; F W Rosa; A M B Menezes; R Pérez-Padilla; J R Jardim Journal: Braz J Med Biol Res Date: 2007-07 Impact factor: 2.590
Authors: Job F M van Boven; Miguel Román-Rodríguez; Josep F Palmer; Núria Toledo-Pons; Borja G Cosío; Joan B Soriano Journal: Chest Date: 2015-12-14 Impact factor: 9.410
Authors: Roberto de Marco; Giancarlo Pesce; Alessandro Marcon; Simone Accordini; Leonardo Antonicelli; Massimiliano Bugiani; Lucio Casali; Marcello Ferrari; Gabriele Nicolini; Maria Grazia Panico; Pietro Pirina; Maria Elisabetta Zanolin; Isa Cerveri; Giuseppe Verlato Journal: PLoS One Date: 2013-05-10 Impact factor: 3.240
Authors: Angelico Mendy; Nervana Metwali; Sarah S Perry; Elizabeth A Chrischilles; Kai Wang; Peter S Thorne Journal: Indoor Air Date: 2019-11-22 Impact factor: 5.770
Authors: Angelico Mendy; Päivi M Salo; Jesse Wilkerson; Lydia Feinstein; Michael B Fessler; Peter S Thorne; Darryl C Zeldin Journal: Ann Am Thorac Soc Date: 2021-12
Authors: Lynn M Baniak; Paul W Scott; Eileen R Chasens; Christopher C Imes; Bomin Jeon; Xiaojun Shi; Patrick J Strollo; Faith S Luyster Journal: J Clin Sleep Med Date: 2022-06-01 Impact factor: 4.324